EDITOR'S CORNER Human Vaccines & Immunotherapeutics 11:9, 2119; August 1, 2015; © 2015 Taylor and Francis Group, LLC
Letter from the Editor Dear reader, In this issue of Human Vaccines & Immunotherapeutics, you will find seven articles on Licensed Vaccines, including reviews on immunity and protection against polio in Europe (Nijsten, p 2123), the significance of combination vaccines in childhood immunization (Maman, p), conditions for optimal herd effects (Scarbrough, p 2142) and vaccination of adults (Tan, p 2158), a research study of Canadian health care providers’ attitude to Tdap vaccine (MacDougall, p 2167), and two commentaries on adult immunization in India (Verma, p 2180) and serious adverse events associated with Yellow Fever vaccine (Martins, p 2183). Three research studies on Pneumococcal vaccines include an analysis of public health and economic impact of PCV in France (Jiang, p 2188), a comparison of safety and immunogenicity of 13- and 23-valent PPV in elderly Japanese subjects (Shiramoto, p 2198), and a study of two-dose catch-up vaccination in children in Mali (Dicko, p 2207). The Novel Vaccines section presents a new chimeric vaccine against Clostridium difficile (Wang, p 2215), a fusion protein derived from Moraxella and Neisseria that can modulate B cells for better protection against meningococcal disease (Mukherjee, p 2223), and a DNA adjuvant encoding domains of cholera toxin and enterotoxin (Bagley, p 2228). We introduce two Influenza articles: an observation that H7N9 epitopes that mimic human proteins may induce Treg-mediated tolerance (De Groot, p 2241), and an analysis of cell-mediated immune response to pandemic 2009 H1N1 vaccines (Chawansuntati, p 2253). In addition, we present a study of Rotavirus vaccine impact on hospital quality of care in Belgium (Standaert, p 2266), a review of Safety of vaccination in patients with auto-immune diseases (Liang, p 2274), and commentaries on the significance of Meningococcal serogroup Y disease in Europe (Broker, p 2281) and on immunotherapeutic possibilities in treatment of HIV (Imami, p 2287). Finally, we are happy that we can bring you a Meeting Supplement from the 8th Vaccine Renaissance meeting this year again. The Guest Editor for this Special Feature is Anne De Groot (Institute for Immunology and Informatics, University of Rhode Island). The supplement features five articles based on presentations at the meeting, which are summarized in an Editorial Introduction (De Groot, p 2294). Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome! Sincerely, Ronald Ellis, PhD Editor-in-Chief Adam Weiss Acquisitions Editor
http://dx.doi.org/10.1080/21645515.2015.1080522
www.tandfonline.com
Human Vaccines & Immunotherapeutics
2119
Letter from the Editor Dear reader, In this issue of Human Vaccines & Immunotherapeutics, you will find seven articles on Licensed Vaccines, including reviews on immunity and protection against polio in Europe (Nijsten, p 2123), the significance of combination vaccines in childhood immunization (Maman, p), conditions for optimal herd effects (Scarbrough, p 2142) and vaccination of adults (Tan, p 2158), a research study of Canadian health care providers’ attitude to Tdap vaccine (MacDougall, p 2167), and two commentaries on adult immunization in India (Verma, p 2180) and serious adverse events associated with Yellow Fever vaccine (Martins, p 2183). Three research studies on Pneumococcal vaccines include an analysis of public health and economic impact of PCV in France (Jiang, p 2188), a comparison of safety and immunogenicity of 13- and 23-valent PPV in elderly Japanese subjects (Shiramoto, p 2198), and a study of two-dose catch-up vaccination in children in Mali (Dicko, p 2207). The Novel Vaccines section presents a new chimeric vaccine against Clostridium difficile (Wang, p 2215), a fusion protein derived from Moraxella and Neisseria that can modulate B cells for better protection against meningococcal disease (Mukherjee, p 2223), and a DNA adjuvant encoding domains of cholera toxin and enterotoxin (Bagley, p 2228). We introduce two Influenza articles: an observation that H7N9 epitopes that mimic human proteins may induce Treg-mediated tolerance (De Groot, p 2241), and an analysis of cell-mediated immune response to pandemic 2009 H1N1 vaccines (Chawansuntati, p 2253). In addition, we present a study of Rotavirus vaccine impact on hospital quality of care in Belgium (Standaert, p 2266), a review of Safety of vaccination in patients with auto-immune diseases (Liang, p 2274), and commentaries on the significance of Meningococcal serogroup Y disease in Europe (Broker, p 2281) and on immunotherapeutic possibilities in treatment of HIV (Imami, p 2287). Finally, we are happy that we can bring you a Meeting Supplement from the 8th Vaccine Renaissance meeting this year again. The Guest Editor for this Special Feature is Anne De Groot (Institute for Immunology and Informatics, University of Rhode Island). The supplement features five articles based on presentations at the meeting, which are summarized in an Editorial Introduction (De Groot, p 2294). Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome! Sincerely, Ronald Ellis, PhD Editor-in-Chief Adam Weiss Acquisitions Editor
http://dx.doi.org/10.1080/21645515.2015.1080522
www.tandfonline.com
Human Vaccines & Immunotherapeutics
2119
